Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
neurofibromin in breast cancer
Original title: “Neurofibromin in Breast Cancer.”
m llerian type high grade serous carcinoma presenting exclusively with pleural lesions and no detectable abdominopelvic primary tumor a case report
Original title: “Müllerian-type high-grade serous carcinoma presenting exclusively with pleural lesions and no detectable abdominopelvic primary tumor: a case report.”
longevity in thalassemia which clock are we trying to slow
Original title: “Longevity in Thalassemia: Which Clock Are We Trying to Slow?”
association between augmented enteral protein and muscle mass attenuation in critically ill patients a sub study of a cluster randomized crossover trial
Original title: “Association between augmented enteral protein and muscle mass attenuation in critically ill patients: A sub-study of a cluster randomized crossover trial.”
tocilizumab treatment for early active phase thyroid eye disease
Original title: “Tocilizumab Treatment for Early Active-Phase Thyroid Eye Disease.”
meier gorlin syndrome caused by compound heterozygous cdc6 variants
Original title: “Meier-GORLIN Syndrome Caused by Compound Heterozygous CDC6 Variants.”
hospital burden and care pathways of anca associated vasculitis in italy a focus on clinical economic and geographic dimensions
Original title: “Hospital Burden and Care Pathways of ANCA-Associated Vasculitis in Italy: A Focus on Clinical, Economic, and Geographic Dimensions.”
identification and relevance of inter tumour heterogeneity in hepatocellular adenoma according to subtypes and the context
Original title: “Identification and relevance of inter-tumour heterogeneity in hepatocellular adenoma according to subtypes and the context.”
single cell atlas of human neutrophils reveals neutrophil heterogeneity across health and disease
Original title: “A single-cell atlas of human neutrophils reveals neutrophil heterogeneity across health and disease.”
different proportions of round headed spermatozoa impacts on sperm function and ivf icsi outcomes
Original title: “Different Proportions of Round-Headed Spermatozoa: Impacts on Sperm Function and IVF/ICSI Outcomes.”
innovative therapies in rheumatoid arthritis car t cells and bispecific antibodies
Original title: “Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.”
New study bolsters recommendations to base initial treatment on clinical response One long-term study reported in 2024 showed that outcomes from early TTT were still good as long as 20 years after starting therapy, although it involved participants in two separate Dutch trials that used different TTT strategies. The current study followed participants in a Norwegian trial called ARCTIC, whose initial results were reported in 2016. It enrolled 230 patients who were randomized to two similar TTT strategies: both had clinical remission as the target, but one also included completely negative ultrasound findings of inflammation at all joints tested. Moreover, the median change in modified van der Heijde-Sharp score for radiographic damage was just 2.0 points (IQR 0.5-4.5). With scores averaging 0.5 at baseline, and a maximum possible score of 448, the authors called this degree of progression "limited" in their report, appearing in Annals of the Rheumatic Diseases. These findings, the investigators wrote, "support current treatment recommendations for RA and offer reassurance to patients newly diagnosed with RA that clinical remission, preserved function, and favorable long-term survival are realistic long-term outcomes." This study examined 10-year outcomes among participants in a stringent treat-to-target trial, with data from 82% of survivors from the original enrollment. More than 80% were in clinical remission at year 10, with "limited" radiographic progression during follow-up. Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. Those who had achieved clinical remission (DAS <1.6) at year 2 were significantly more likely to keep that status at year 10 (89.9%), compared with those with poorer short-term outcomes (73.1%, P=0.01). Other outcomes including the more conventional 28-joint DAS, ultrasound findings, ACR/EULAR 2.0 remission, and measures of systemic inflammation all showed significantly more disease activity at year 10, albeit still generally low, among those not reaching remission at year 2.
Original title: “Excellent 10-Year Outcomes After Early Treat-to-Target in Rheumatoid Arthritis | MedPage Today”